Generic Peptides Somatropin 100 to 200 IU HGH Kits for Sale
Out of stock
Injection · 2 mg · vial
Generic Peptides Tirzepatide is a dual GIP and GLP-1 receptor agonist peptide, a lyophilized powder supplied for laboratory research in three vial sizes: 2 mg, 5 mg and 10 mg.
GMP-manufactured, each batch is HPLC-verified with the Certificate of Analysis on file. Tirzepatide for sale with international shipping and dispatch within two business days after payment.
Generic Peptides Tirzepatide is a dual receptor agonist that engages the GIP and the GLP-1 receptor, supplied as a lyophilized research powder in 2 mg, 5 mg and 10 mg vials. A fatty di-acid on a lysine linker holds it in circulation for days, and the single agonist Semaglutide and the triple agonist Retatrutide are the comparison points.
Same dual agonist peptide in three strengths.
| Variant | Dosage | Form and quantity | Best use |
|---|---|---|---|
| Tirzepatide 2 mg | 2 mg | Vial | Short |
| Tirzepatide 5 mg | 5 mg | Vial | Standard |
| Tirzepatide 10 mg | 10 mg | Vial | Extended |
The 10 mg vial carries five times the material of the 2 mg vial, which matters when a protocol samples on several days. This line pairs the peptide with a fragment such as AOD 9604 or Adipotide in a separate arm.
The molecule activates two incretin receptors instead of one, and GIP with GLP-1 signalling shapes appetite, gastric emptying and glucose-dependent insulin release. The chain is based on the GIP sequence, with two non-natural amino acids at positions 2 and 13 and a long fatty di-acid on a lysine linker.
Dissolve the powder with sterile or bacteriostatic water, which is not included, and swirl instead of shaking. Divide the milligrams on the vial by the millilitres added to read mg per mL. Keep the sealed powder at 2-8 C or -20 C and use the mixed solution within about four weeks.
No research dose is stated here and the vial is not a medicine. Licensed tirzepatide injections are given once weekly under a physician with a step-up schedule and carry a boxed warning for thyroid C-cell tumours in rodents.
Supplied for laboratory research only, not for human or veterinary use. Information provided is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before use.
| Trade Name | Tirzepatide |
| Generic Name | Tirzepatide (dual GIP and GLP-1 agonist) |
| Manufacturer | Generic Peptides |
| Dosage | 2 mg, 5 mg or 10 mg per vial |
| Package | Lyophilized powder, one vial |
| Drug Class | Incretin peptide; dual GIP and GLP-1 agonist |
| Administration | Subcutaneous (research protocols) |
| Storage | Lyophilized 2-8 C or -20 C; mixed 2-8 C, 4 weeks |
| Prescription Status | Research use only |
| Verification | Batch details confirmed with supplier |
| Shipping | International shipping, about USD 35; no USA option on this offer |
For laboratory research only. Consult a healthcare professional before handling any peptide. Amounts shown are research references, not recommended human doses.
Before you ask
It is a dual agonist peptide that activates the GIP and GLP-1 receptors at the same time. Chemically it follows the GIP sequence with two non-natural amino acids at positions 2 and 13, a C-terminal amide, and a lysine at position 20 linked to 1,20-eicosanedioic acid. The FDA label gives its mass as 4813.53 Da and its formula as C225H348N48O68.
No. The vials on this page are lyophilized research material for laboratory work only. The approved tirzepatide medicines are prescription products injected once weekly under medical supervision, and they carry a boxed warning. No human dose is stated or implied here, and the material is not for human or veterinary use.
Keep the sealed powder cool, dry and dark, at 2-8 C for routine work and -20 C for long-term storage, and let the vial warm to room temperature before opening because the powder takes up moisture. Dissolve it in sterile or bacteriostatic water down the vial wall and swirl gently. Keep the solution at 2-8 C for about four weeks.
The label lists gastrointestinal reactions as the most common: nausea, diarrhoea, vomiting, constipation, indigestion and abdominal pain, along with injection-site reactions and tiredness. Serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, hypoglycaemia with insulin or sulfonylureas, and thyroid C-cell tumours in rodents.
It is not on the WADA Prohibited List. WADA has placed the GLP-1 receptor agonist class, including semaglutide and tirzepatide, in its Monitoring Program, which means samples are screened to study how widely these drugs are used, and WADA has said the status stays unchanged for 2027. Monitoring is not a prohibition.
Semaglutide acts on one receptor, GLP-1, while tirzepatide activates GIP as well. The two therefore differ in receptor coverage and in the trial profiles published for each, but neither is a research material by design. In this line the comparison is run as two separate arms so the receptor count is the only variable.
All three vial sizes are listed on this page as research material with international shipping at checkout, handled in one to two days with a transit window of four to ten days. Shipping runs about 35 dollars. The U.S. domestic option is not offered on this offer, so buyers inside the United States should check the rules that apply to them.
Be the first to share your experience with Generic Peptides Tirzepatide 2 to 10 mg GIP GLP-1 Vials
Log in to write a reviewComplete the cycle
Out of stock
Out of stock
Out of stock